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Abstract 
Background: Immunotherapy of patients suffering from the human epidermal growth factor receptor 2 overex-
pressing (HER-2+) breast cancers with the anti-HER-2 antibodies results in increase of the patients’ overall survival. 
However, no prophylactic vaccine is available against HER-2+ breast cancers. Although, prophylactic vaccine for 
human hepatitis B virus (HBV) is very effective.
Specific aim: The specific aim of this work was to design, synthesize, and test bio-molecules which would engage 
prophylactic immunity against hepatitis B virus towards killing breast cancers cells.
Methods and Results: By biomolecular engineering, we have created a novel family of biomolecules: antibody 
(anti-HER-2) × vaccine (HBsAg) engineered constructs (AVEC: anti-HER-2 × HBsAg). These biomolecules were utilized 
for redirecting, accelerating, and amplifying of the vaccination-induced, prophylactic immunity originally targeted 
against HBV as therapeutic immunity, newly targeted against HER-2+ breast cancers. Treatment of the HER-2+ breast 
cancer cells with AVEC: anti-HER-2 × HBsAg in blood of the patients, vaccinated with HBsAg, rapidly increased efficacy 
of killing of HER-2+ breast cancer cells over that attained with the naked anti-HER-2 antibodies.
Conclusion: Novel antibody-vaccine engineered constructs (AVEC) facilitate redirecting, accelerating, and amplifying 
of prophylactic, HBV vaccination-induced immunity as immunotherapy (RAAVIIT) of HER-2+ breast cancer. We cur-
rently streamline this novel therapeutic paradigm into clinical trials of breast and other cancers.
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Background
According to the Centers for Disease Control and Pre-
vention, 220,097 women were diagnosed with the breast 
cancer—the highest incidence of all female cancers—in 
the USA in 2011 [1]. Almost 30 % of those cancers over-
expressed genes Erbb-B2; thus diagnosed as HER-2+ 
breast cancers. These cancers are associated with shorter 
times to relapses, as well as, shorter overall survivals, 
than those that did not overexpress Erb-B2 (HER2-). 
These data strongly support administering immunother-
apy with antibodies against HER-2 [2–5]. Two domains 
of the HER-2 receptors are targeted by antibodies 
currently approved by the FDA: trastuzumab (Herceptin) 
and pertuzumab (Perjeta) [6, 7]. In combination with the 
M-phase specific systemic therapeutic-docetaxel, they 
result in a total survival of more than 4.5 years, compared 
with 1.5 years achieved 14 years ago [8]. Mechanisms of 
action include: (I) inhibition of growth by steric inhibi-
tion of receptors’ dimerization; (II) antibody-dependent 
cell-mediated cytotoxicity (ADCC); (III) complement 
dependent cytotoxicity (CDC) [8–11]. Therefore, efficacy 
of this immuno-therapy relies heavily upon engaging 
the patients’ own immune system, as well as repressing 
resistance [12].
Ideally, the most effective way to reduce such a high 
incidence of breast cancers would be vaccination. Unfor-
tunately, there are no breast cancer vaccines that are 
approved by the FDA. The clinical trials with various 
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anti-cancer vaccines resulted in the overall efficacy in the 
range of 2.6 % so far [13, 14]. This is nowhere near the great 
efficacy of anti-viral and anti-bacterial vaccines, which are 
approved by the FDA and recommended by the CDC [15].
Vaccination against various microbials is the greatest 
achievement of the modern medicine. In particular, the 
vaccines against hepatitis B virus (HBV) are approved by 
the FDA and recommended by the CDC: Engerix B and 
Recombivax [16–18]. Measure of the immune system 
readiness is production of antibodies by immune cells at 
the titers above 10.0  mIU/ml. If the antibody titer falls 
below that aforementioned value, the booster dose quickly 
reinvigorates the effective immunity. Thanks to this pro-
gram in the USA, incidence of Hepatitis B declined 82 % 
over 17 years, i.e., from 8.5 cases per 100,000 population 
in 1990 to 1.5 cases per 100,000 population in 2007.
In clinical practice, we realized presence of a strange 
paradox. On one hand we have populations of patients, 
who are having their entire active immunity system, 
enhanced due to the FDA approved HBV vaccine, 
remaining on stand-by. On the other hand, we have 
populations of patients, who were diagnosed with breast 
cancers carrying specific molecules HER-2—a potential 
vaccination target and who would greatly benefit from 
therapeutic vaccines, but no vaccines are available. This 
realization prompted our work.
Specific aim
The specific aim of this project was biomolecular engi-
neering of molecules capable of redirecting, accelerating, 
and amplifying immunity from the preventive immunity, 
attained due to HBsAg vaccination against hepatitis B 
viruses, towards the therapeutic immunity against HER-
2+ breast cancers.
Patients
Blood and cancer biopsies were acquired from the ten 
patients suffering from the advanced breast cancers, from 
the Acute and Chronic Infection with Hepatitis B virus, 
and from the healthy volunteers having high titers of 
antibodies induced by standard HBsAg vaccination. All 
biopsies were acquired in accordance with the Declara-
tion of Helsinki, Institutional Review Board approval, and 
with Patients’ Informed Consent (PIC).
Experimental design
The experimental design is illustrated (Fig.  1). The novel 
molecule antibody  ×  vaccine engineered construct 
(AVEC): anti-HER-2  ×  HBsAg contains the three main 
effector domains: (1) constant fragment receptor (FcR) 
binding domain; (2) C1q complement docking domains; (3) 
hepatitis B surface antigen (HBsAg), which is the HBV VLP. 
All are guided by the complementarity determining regions 
(CDRs) within variable fragment domains targeting human 
epidermal growth factor receptor 2 (HER-2) Fig. 1.
Methods
Breast cancer cells
SK-BR-3—human breast cancer cell line was from the 
American Type Culture Collection (ATCC, Rockville, 
MD, USA) [19]. It was derived from the pleural effusion 
in tractu of the advanced, metastatic breast adenocarci-
noma. It was overexpressing Erb-B2 gene to display HER-2 
receptors. It was cultured in the base medium: McCoy’s 
5a medium (ATCC) (catalog No. 30-2007), which was 
supplemented with 10 % human serum, 100 units/ml pen-
icillin, 200 mg/ml streptomycin, in the cell culture 75 cm2 
flask (Corning) (catalog #430641) in the CO2 incubators 
at 37 °C. The medium renewal was performed two times 
per week. To split, the cultures were briefly rinsed with 
0.25 % (w/v) trypsin, 0.53 mM EDTA solution to remove 
all traces of serum which contains trypsin inhibitor and 
thereafter treated with that solution. After dispensing into 
new flasks, they were grown in the same conditions.
MCF-7—human breast cancer cell line was from the 
ATCC. It was derived from the pleural effusion in tractu 
of the advanced, metastatic mammary gland epithelial 
carcinoma. It was not overexpressing the Erb-B2 gene, 
but was overexpressing estrogen and progesterone recep-
tors [20]. It was used as a negative control foe HER-2 
expressing cells. It was cultured in the base medium: 
Eagle’s minimum essential medium (ATCC) (catalog No. 
30-2003), which was supplemented with 10  % human 
serum, 0.01  mg/ml human recombinant insulin (hrI), 
100  units/ml penicillin, 200  mg/ml streptomycin, in the 
cell culture 75  cm2 flask (Corning) (catalog #430641) in 
the incubators providing 95 % air and 5 % CO2 at 37 °C. 
The medium renewal was two times per week and cul-
tures divided as outlined above.
Biotechnology of anti‑HER‑2 and anti‑HBsAg antibodies 
and biosimilars
Biotechnology of anti-HER-2 antibodies synthesis was 
pursued by adaptation of that originally described, either 
as new antibodies or as biosimilars to the FDA approved: 
trastuzumab and pertuzumab as the positive controls [21, 
22]. For verification, the DNA plasmid constructs for the 
anti-HER-2 antibodies variable fragments were imported 
from the international ImMunoGeneTics (IMGT, Paris, F, 
EU) antibody sequences’ bank [23, 24].
Briefly, in the first technology, the B cells were isolated 
from the blood of patients suffering from the cancers. White 
blood cells (WBC) were isolated using Ficoll-Hypaque tech-
nique. The total mRNA was isolated using Trizol reagent 
(Molecular Research Center, Inc. Cincinnati, OH). The 
cDNA was generated using random hexamers (Intergrated 
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DNA Technologies, Coralville, IA) and reverse transcriptase 
(Promega, Madison, WI) in reactions involving denatur-
ing RNA at 70  °C followed by reverse transcription car-
ried at 42  °C for 15 min. The cDNA quality was tested by 
the polymerase chain reaction (PCR) of beta actin and 
GAPDH as reference genes with the commercially available 
primers (ABI, Foster City, CA). For amplification of coding 
sequences of the variable fragments, the primers sets were 
designed using the Kabat database. They were synthesized 
on 380A DNA Synthesizer (ABI, Foster City, CA). The vari-
able fragments were amplified with polymerase chain reac-
tion using the mix of the generated cDNA, the synthesized 
primers, dNTPs, and Taq DNA polymerase (Hoffmann–
La Roche, Basel, Switzerland) on the Robocycler (Strata-
gene, San Diego, CA) or Mastercycler (Eppendorf, New 
York, NY). The blunt ended amplicons were inserted into 
the plasmid coding for the constant regions of the human 
antibodies with sequences imported from the Gene Bank. 
The DNA plasmid construct also contained metal bind-
ing domains capable of chelating superparamagnetic and 
fluorescent metals as detailed [21]. After electroporation of 
plasmids into fresh B cells or cultured human myelomas, 
they were propagated and expressed as described [22].
For selection and in  vitro evolution, the HER-2 recep-
tors were extracted from the human HER-2+ breast cancer 
cells by immunoprecipitation of rapidly frozen, crushed, 
thawed, and lyophilized. Alternatively, the mimotopes of 
HER-2 were manufactured. Both served as the molecular 
baits and references for validation of antibodies.
Alternatively, biotechnology of trastuzumab and per-
tuzumab biosimilars was crafted on such a way that the 
coding sequences for the anti-HER-2 antibodies’ vari-
able fragments were imported from the IMGT. These 
sequences were synthesized, cloned, expressed, and mod-
ified on the same way as the newly developed anti-HER-2 
antibodies as described above.
For generating of anti-HBsAg antibodies the B cell were 
acquired from the patients suffering from the Acute and 
Chronic Hepatitis B. The protocol was identical to that 
published (22). Dane particles, isolated from the patients’ 
blood by PEG gradients precipitation or from liver biop-
sies by CsCl gradient centrifugations, were rapidly frozen, 
lyophilized and stored. Alternatively, HBsAg were pro-
duced in human hepatoma cells transfected with plasmid 
DNA. Prior to selection, during in  vitro evolution, they 
were reconstituted with buffer and served as the molec-
ular baits. They also served as the negative controls for 
anti-HER-2 antibodies.
The metal binding domains of the antibodies were 
saturated with Gd, Tb, Ru, Ni, Co, or Eu or linked with 
Au coated Fe3O4 [Au(Fe3O4)] nanoparticles. The speci-
ficity and sensitivity were determined based upon ele-
mental spectra acquired with EDXS (Noran, Middleton, 
WI, USA), EELS (Zeiss, Oberkochen, D, EU), or TRXFS 
(Bruker AXS, Fitchburg, WI, USA). The fluorescent 
properties were measured with the RF-5301PC spec-
trofluorometer (Shimadzu, Tokyo, Japan). The magnetic 
relaxivities were measured on the DMX 400 WB or 
AVANCE II NMR spectrometers (Bruker Optics, Dal-
las, TX, USA). Specificity and sensitivity towards specific 
domains of the receptor were tested by cross-blocking 
(Table 1).
Biotechnlogy of HBsAg
HBsAg was isolated from the patients suffering from 
Acute and/or Chronic Hepatitis B: either from the blood 
by PEG fractionations or from the liver biopsies by CsCl 
gradient centrifugation.
To assure exact immunogenic compatibility with the 
immunity induced by vaccinations with the FDA approved 
HBsAg, which were produced in yeast, the HBsAg in 
this project were also generated in yeast as originally 
described [25, 26]. Biotechnology of the recombinant 
HBsAg was pursued based upon the published DNA cod-
ing sequence. Hepatitis B virus like particles (VLP) were 
initially synthesized in yeast—Saccharomyces cerevisiae as 
originally described. In particular, the expression plasmid 
pHBS-16 included the HBsAg surface antigen (HBsAg) 
controlled by the yeast alcohol dehydrogenase (ADHI) 
promoter through introduced by EcoRI restriction sites 
into the DNA construct of the pBR322 plasmid. That fol-
lowed by yeast replication origin, yeast trp1 gene. This 
biotechnology was later modified to be pursued in Pichia 
pastoris [27]. Briefly, yeast cultures of Pichia pastoris were 
Fig. 1 Functional organization of AVEC: anti-HER-2 × HBsAg. 
Antibody x vaccine engineered construct (AVEC): anti-HER-2 x 
HBsAg consists of the targeting and effector domains. The targeting 
domains constitute the complementarity determining regions (CDRs) 
for human epidermal growth factor receptor 2 (HER-2). The effector 
domains constitute: hepatitis B surface antigen (HBsAg); constant 
fragment receptor binding domain (FcR-BD); complement system 
binding domain (CS-BD)
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grown at 30  °C in rich medium (YPD; 1 % yeast extract, 
2 % bactopeptone, 2 % glucose) initially and shifted either 
to synthetic media (YNM, 0.67 % yeast nitrogen base sup-
plemented with 0.5  % (v/v) methanol) for immunopre-
cipitation and immunofluorescence experiments, or to 
mineral media (MMOT, 0.2 % (v/v) oleate and 0.02 % (v/v) 
Tween-40) for fractionation studies.
All the protocols’ products—HBsAg VLPs were refer-
enced and validated to the FDA approved and the CDC 
recommended Engerix B and Recombivax and standard 
clinical diagnostics.
Biotechnology of fluorescent and superparamagnetic 
mimotopes
Design of HER-2 cyclic mimotopes was initiated by 
importing the DNA from the GenBank and in vitro trans-
lation into amino acid sequences or direct amino acid 
sequences from SwissProt into the Peptide 3D or Laser-
Gene software. That followed by determination of surface 
displayed domains. Further analysis led to selection of 
the most likely immunogenic domains. The 12–40 amino 
acids long sequences were selected. The amino acid 
sequences were exported directly into the program of the 
peptide synthesizer (ABI, Foster City, CA). The selected 
sequences were altered by introducing glycine linkers 
with terminal cysteines at both amino and carboxyl ter-
minus of the peptide designs. The designed peptides were 
synthesized as linear on the peptide synthesizer. After 
detachment from the cartridges, the peptides were con-
verted into cyclics by means of the cysteines. The syn-
thetic products—HER-2 mimotopes were selected on the 
high pressure liquid chromatography columns.
The specificity of the mimotopes was validated by bind-
ing to trastuzumab and ant-HER-2 antibodies with the 
aid of MACS or FACS.
Biotechnology of anti‑HER‑2 × HBsAg biomolecular 
clusters
The synthetic anti-HER-2 antibodies and synthetic 
HBsAg VLPs were linked with heterospecific, bifunc-
tional linker—sulfo-m-maleimidobenzoyl-N-hydroxysuc-
cinimide ester (SMBS) after adapting the protocol [28]. 
Briefly, the anti-HER-2 antibody was dialyzed against 
0.15 M sodium chloride, 0.1 M sodium phosphate, at pH 
7.2. Sulfo-MBS stock in DMSO was added to this solution 
up to the final 2 % w/v concentration to assure at least 80x 
molar excess. After 1  h at room temperature, the reac-
tion solution was rapidly applied to desalting columns. 
Performing chromatography with the 0.15  M sodium 
chloride, 0.1 M sodium phosphate, at pH 7.2 carrier solu-
tion was followed by pooling the activated anti-HER-2 
antibodies 1 ml fractions. To this solution, the synthetic 
HBsAg diluted in the same carrier solution was promptly 
added to assure 1:1 ratio. The reaction continued for 1 h 
at room temperature. The effective anti-HER-2 × HBsAg 
clusters were isolated by chromatography.
The specificity of the anti-HER-2  ×  HBsAg to label 
HER-2 receptors was validated by FCM on cells and by 
NMR and XRFS on mimotopes. The specificity of the 
anti-HER-2  ×  HBsAg to attract immune response was 
validated by labeling with anti-HBsAg antibodies ren-
dered fluorescent for FCM or superparamagnetic for 
NMR [21].
Immunoblotting and immunoprecipitation
The cells and tissues were either frozen crushed in the 
rapid controlled rate freezer (NSF grant support to MM).
or native disintegrated with ultrasonicator (Branson 
Ultrasonic, Danbury, CT, USA). After being homoge-
nized within the sample buffer they were either stored in 
liquid nitrogen or lyophilized. They were electrophoresed 
in the native buffer (Invitrogen, Carlsbad, CA, USA). 
They were vacuum- or electro-transferred onto the PVDF 
membranes (Amersham, Buckinghamshire, UK, EU). The 
membranes carrying the transferred proteins were first 
soaked within human serum and thereafter labeled with 
the bioengineered, biosimilar, and referenced anti-HER-2 
antibodies. The anti-HBsAg isotype antibodies served as 
the controls. The images of the blots were acquired and 
quantified with Fluoroimager (Molecular Dynamics, 
Sunnyvale, CA, USA) or Storm 840 (Amersham, Buck-
inghamshire, UK, EU).
Table 1 Cross-blocking of AVEC: anti-HER-2 × HBsAg
Trastuzumab Anti‑HER‑2001 Anti‑HER‑2004 Anti‑HER‑2001 × HBsAg Anti‑HER‑2004 × HBsAg Anti‑HBsAg
Trastuzumab + + − + − −
Anti-HER-2001 + + − + − −
Anti-HER-2004 − − + − + −
Anti-HER-2001 × HBsAg + + − + − −
Anti-HER-2004 × HBsAg − − + − + −
Anti-HBsAg − − - − − +
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The anti-HER-2 and anti-HBsAg antibodies were ren-
dered magnetic or fluorescent by conjugating Au coated 
Fe3O4 nanoparticles or fluorochromes. The sera and liver 
biopsies’ homogenates were mixed with these superpara-
magnetic antibodies. The targeted molecules rendered 
fluorescent were pulled out by the means of 1.5T mag-
net. The intensity of fluorescence was measured on the 
spectrofluorometer.
Fluorescent antibodies. Fluorescent, activated cell sorting. 
Flow cytometry. Multiphoton fluorescence spectroscopy
 SK-BR-3, MCF-7, and patients’ breast cancer cells were 
labeled with the fluorescent antibodies. They were sorted 
on the Calibur, Vantage SE, or Aria (Becton–Dickinson, 
Franklin Lakes, NJ, USA). The antibodies were dissolved 
and all washing steps carried in phenol-free, Ca+/Mg+ 
free, PIPES buffered saline solution, supplemented with 
20  mM glucose, 10  % human serum. Sorting was per-
formed on Aria, Calibur, Vantage SE (Becton–Dickinson, 
Franklin Lakes, NJ, USA) with the sheath pressure set at 
20  lb per square inch pressure and low count rate. The 
sorted batches were analyzed on Calibur or Aria using 
FACS Diva software or on the FC500 (Beckman-Coul-
ter, Brea, CA, USA). For the measurement of the fluo-
rescently labeled cells, these settings were tuned at the 
maximum emission for the Eu chelated antibody at 500 V 
with references to isotype antibodies and non-labeled 
cells. This assured the comparisons between populations 
of cells labeled with multiple antibodies without chang-
ing the settings on PMTs.
The fluorescently labeled cells or tissues were imaged 
with the Axiovert (Zeiss, Oberkochen, D, EU) equipped 
with the Enterprise argon ion (457, 488, 529  nm lines) 
and ultraviolet (UV) (364  nm line) lasers; Odyssey XL 
digital high-sensitivity with instant deconvolution con-
focal laser scanning imaging system operated up to 240 
frames/s (Noran, Madison, WI, USA), and the Diaphot 
(Nikon, Tokyo, Japan) equipped with the Microlase 
diode-pumped Nd:YLF solid state laser (1048 nm line).
Superparamagnetic antibodies. Nuclear magnetic 
resonance spectroscopy. Magnetic activated cell sorting
SK-BR-3, MCF-7, and the patients’ breast cancer cells 
were labeled with the super paramagnetic anti-HER-2 
and anti-phosphatidylserine (anti-PS) antibodies pro-
pidium iodide, and bisbenzimide (40). The antibodies 
were dissolved and all washing steps carried in phenol-
free, Ca+/Mg+ free, PIPES buffered saline solution, sup-
plemented with 20  mM glucose, 10  % human serum. 
The aliquots were dispensed into the magnetism-free 
NMR tubes (Shigemi, Tokyo, Japan). The relaxation times 
T1 were measured in resonance to the applied pulse 
sequences on the NMR spectrometers: DMX 400 WB or 
AVANCE II NMR (Bruker, Billerica, MA) or the Signa 
clinical scanners (GE, Milwaukee, WI, USA).
The superparamagnetic antibodies were also used to 
isolate the labeled cells from the solution. The cancer 
cells labeled with the superparamagnetic antibodies were 
isolated on the magnetic, activated cell sorter operated at 
1.5T (NSF grant support to MM).
Elemental‑tags modified antibodies. Energy dispersive 
X‑ray spectroscopy. X‑ray reflection fluorescence 
spectroscopy
The samples, which were cryo-immobilized, presented 
the life-like antigenicity and supramolecular organiza-
tion. Elemental analyses were pursued by EDXS and 
XRFS as described [21]. The field emission, scanning 
transmission, electron microscope FESTEM HB501 (Vac-
uum Generators, Kirkland, WA, USA) was equipped with 
the energy dispersive X-ray spectrometer (EDXS) (Noran, 
Middleton, WI, USA) and post-column electron energy 
loss spectrometer (EELS) (Gatan, Pleasanton, CA). The 
cryo-energy filtering transmission electron microscope 
912 Omega was equipped with the in-column, electron 
energy loss spectrometer (EELS) and the energy disper-
sive X-ray spectrometer (EDXS) (Zeiss, Oberkochen, 
D, EU). The cryo-energy filtering transmission electron 
microscopes 410 and 430 Phillips were equipped with the 
post-column, electron energy loss spectrometers (EELS) 
and the energy dispersive X-ray spectrometer (EDXS) 
(Noran, Middleton, WI, USA). The field emission, scan-
ning electron microscope SEM1530 (Zeiss, Oberkochen, 
D, EU) was equipped with the energy dispersive X-ray 
spectrometer (EDXS) (Noran, Middleton, WI, USA). 
The field emission, scanning electron microscope 3400 
was equipped with the energy dispersive X-ray spec-
trometer (EDXS) (Hitachi, Tokyo, Japan). The S2 Picofox 
XRFS spectrometer was equipped with a molybdenum 
(Mo) X-ray target and the Peltier cooled Xflash Silicon 
Drift Detector (Bruker AXS, Fitchburg, WI, USA). Scan 
times ranged up to 1000s. The ICP standard of 1000 mg/l 
of mono-element Gallium or Gadolinium (CPI Interna-
tional, Denver, CO, USA) was added to 500  μl of each 
sample to the final concentration of 10 mg/l. Instrument 
control, data collection, and analysis were under the 
SPECTRA 7 software (Bruker AXS, Fitchburg, WI, USA).
Antibody dependent redirected‑vaccination‑induced 
immunity toxicity (ADRIT)
To study collective killing effects of the anti-HER-2 and anti-
HER-2 × HBsAg upon the breast cancer cells, the patients’ 
cell and serum fraction described below were pooled 
making erythrocytes-free blood (EFB). Anti-HER-2 and 
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anti-HER-2 × HBsAg were added to the EFB. So were, anti-
HBsAg, anti-HPV, anti-HSV, EGFR1, and isotype antibodies 
as the controls. The incubation with the antibodies con-
tinued at the 37  °C incubators. The labeling continued for 
1–24 h. It was terminated by washing with the cold buffer.
To quantify the numbers of killed cells by flow cytom-
etry (FCM) and fluorescent activated cell sorting (FACS) 
the samples were stained with propidium iodide (PI) 
(Sigma-Aldrich, Milwaukee, WI, USA) used at 50 µg/ml. 
To determine the numbers of apoptotic cells, they were 
labeled with anti-phosphatidylserine antibodies.
Antibody dependent cell cytotoxicity (ADCC)
To study toxicity to the breast cancer cells caused by the 
patients’ cytotoxic cells—the effectors triggered by the 
anti-HER-2 antibodies, the peripheral blood mononuclear 
cells were separated from the blood on Ficoll-Hypaque 
density gradients. The cells were washed by three cycles of 
spinning down and suspending in the PBS at pH 7.3. They 
were rendered fluorescent by adding the stock solution of 
the DiI membrane dye (Molecular Probes, Inc., Eugene, 
OR, USA) in DMSO for 10 min at 26  °C. Small aliquots 
were washed with the buffer and the cells quantified on 
FCM as the way to determine the effector to target cells’ 
ratios (ETR). These ratios varied: 10:1, 50:1, and 100:1. 
Incubations lasted 1–7 h in a 37 °C, 5 % CO2 incubator.
The numbers of killed cells were determined due to 
staining with the PI at 50 µg/ml and of surviving cells from 
the DiO staining counts and thymidine incorporation.
Complement dependent cytotoxicity (CDC)
To study toxicity to the breast cancer cells caused by the 
patients’ complement system—the effector, the serum 
was separated by gentle centrifugation from the freshly 
drawn blood. It was supplemented with the anti-HER-2 
and anti-HER-2  ×  HBsAg. Incubations lasted 1–7  h in 
a 37  °C, 5 % CO2 incubator. The numbers of killed cells 
were determined due to staining with the PI at 50 µg/ml 
and of surviving cells from the DiO staining counts and 
thymidine incorporation.
Statistical analysis
All the measurements were run in triplicates for each 
sample from six patients. The numbers were analyzed 
and displayed using GraphPad software (GraphPad Soft-
ware, Inc, La Jolla, CA). Data were presented as mean of 
standard error of the mean (SEM). Statistical significance 
was calculated by t test for two groups.
Results
Sensitivity and specificity of AVEC: anti‑HER‑2 × HBsAg 
in targeting of breast cancer cells and human breast 
epithelial (HBE) cells
The diagram of the antibody × vaccine engineered con-
struct (AVEC): anti-HER-2  ×  HBsAg—the novel syn-
thetic bio-molecule is shown (Fig. 1). It consists of the two 
main sets of domains: targeting: anti-HER-2 antibody and 
effector: HBsAg—vaccines; FcR-BD–Fc receptor binding 
domain; and CD-BD—complement system binding domain. 
Therefore, one of the most essential factors for attaining 
high efficacy of targeted immunotherapy is its specificity 
and sensitivity in targeting the HER-2 receptor and HBsAg.
We measured sensitivity of detection of HER-2 on can-
cer cells by labeling cells with superparamagnetic anti-
bodies and measuring relaxivities by nuclear magnetic 
resonance (NMR) (Fig. 2a). For this purpose, the SK-BR-
3, MCF-7, patients’ breast cancer cells, and human breast 
epithelial cells were labeled with trastuzumab, anti-
HER-2001, anti-HER-2004, anti-HER-2001  ×  HBsAg, and 
anti-HER-2004 × HBsAg and anti-HBsAg. As the control, 
(See figure on next page.) 
Fig. 2 Sensitivity and specificity of anti-HER-2 × HBsAg. a The breast cancer cells were labeled with trastuzumab, anti-HER-2001  × HBsAg, 
anti-HER-2004 × HBsAg, anti-HBsAg (anti-HB) and relevant isotype antibodies (iso) as indicated, followed by secondary superparamagentic antibod-
ies. Measured changes in relaxivities reflect specificity and sensitivity of labeling. All experiments were conducted three times. The data presented are 
representative for all. The SK-BR-3 and the patients’ breast cancer cells (BC001 - the data for the patient 001 are representative to all 10 patients) cells 
were heavily labeled with trastuzumab, anti-HER-2 antibodies, and anti-HER-2 × HBsAg constructs. The MCF-7 and the patients’ human breast epi-
thelial cells (HBE) were not labeled at the statistically significant relaxivity change. The isotype antibodies did not label the breast cancer and healthy 
cells. b Sera of patients with high titers of anti-HBsAg antibodies were rapidly cryoimmobilized, crushed, thawed, immunoprecipitated with super-
paramagnetic molecular baits as indicated, released into electrophoresis, and immunoblotted. Lanes’ of superparamagnetic immunoprecipitation 
labels. 1. Immuno-naïve patient, not immunized, not infected, tested with the clinical diagnostics. 2. Vaccinated patient tested with anti-HER-02001 
x HBsAg; 3 Vaccinated patient tested with isotype antibody; 4. Vaccinated patient tested with anti-HER-02004 x HBsAg; 5. Vaccinated patient tested 
with isotype antibody; 6. Vaccinated patient tested with Engerix; 7. Vaccinated patient tested with isotype antibody; 8. Vaccinated patient tested with 
Recombivax; 9. Vaccinated patient tested with isotype antibody; 11. Vaccinated patient tested with anti-HBsAg isotype antibody 10, 12 molecular 
weight standards. Three experiments provided the same data. All molecular baits used in this study were pulling out the same anti-HBsAg mol-
ecule as determined by Hepatitis B clinical diagnostic assays. (c) The blots from (b) were quantified at high sensitivity and revealed only anti-HBsAg 
antibodies in the patients sera and no other molecules immunoprecipitated and labeled. (d–m) The breast cancer cells were labeled with trastu-
zumab (d), anti-HER-2004 × HBsAg (e) mix of both tagged with different flurochromes, (f) anti-HER-2001 × HBsAg followed by anti-HBsAg fluorescent 
antibodies (g) or after initial labeling with anti-HER-2001 × HBV, the cells were labeled with trastuzumab. (h, i) Isotype antibodies for trastuzumab (j) 
anti-HER-2001 (k) anti-HER-2004 (l) anti-HBsAg (m) did not reach statistically significant counts of the labelled cells
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the MCF-7 cells, which do not overexpress HER-2, were 
labeled with the same antibodies. As the control, these 
cells were also labeled with the isotype antibodies. The 
measurements revealed statistically significant differ-
ences between the HER-2+ SK-BR-3 and patients’ HER-
2+ breast cancer cells, which were heavily labeled with 
therapeutics: trastuzumab, anti-HER-2001, anti-HER-2004, 
anti-HER-2001  ×  HBsAg, and anti-HER-2004  ×  HBsAg 
versus the HER-2− MCF-7  and human breast epithelial 
cells, which were practically not labeled. These meas-
urements revealed also statistical differences between 
these therapeutics and the isotypes. Therefore, we vali-
dated efficient targeting of the HER-2+ SK-BR-3 and the 
patients’ HER-2+ breast cancer cells (the measurements 
included are representative for all 10 patients’ biopsies 
studied) breast cancer cells by the anti-HER-2 × HBsAg.
We measured specificity of targeting of the HBsAg by 
vaccinated and infected patients’ antibodies, while meas-
uring the concentration of this immunogen immuno-
precipitated, which was electrophoresed, immunoblotted 
(Fig.  2b, c). All molecular baits used in this study were 
pulling out the same 150 kDa molecule, which was rec-
ognized by clinical diagnostics for Hepatitis B. By quan-
titative high gain scanning of the blots, we were able to 
determine that there were no other molecules pulled 
out from the sera. The same experiments conducted on 
the sera of not immunized patients resulted in empty 
lanes (Fig.  2b, c). Therefore, we concluded that anti-
HER-2001  ×  HBsAg and anti-HER-2004  ×  HBsAg were 
targeted the same molecule anti-HBsAg.
Finally, we determined specificity and sensitivity of the 
HER-2 domains’ targeting by flow cytometry (Fig.  2). 
Moreover, we performed tests of cross-blocking (Table 1). 
While labeling with anti-HER-2001 × HBsAg interfered on 
the statistically significant level with trastuzumab, labe-
ling with anti-HER-2004 ×  HBsAg did not. Therefore, we 
concluded that these antibodies: trastuzumab and anti-
HER-2001 × HBsAg target the same, but anti-HER-2004 the 
different domains on the HER-2 receptors.
Mechanism of action of anti‑HER‑2 × HBsAg in breast 
cancer cells’ killing
The three main mechanisms, attributed to the therapeu-
tic efficacy of trastuzumab and pertuzumab, are: growth 
inhibition, apoptosis, and necrosis. We performed the 
relevant tests in relation to our AVEC: anti-HER-2 × 
HBsAg (Fig. 3).
Treatment of the breast cancer cells with increasing 
concentrations of trastuzumab, anti-HER-2 biosimilars, 
and the novel anti-HER-2001  ×  HBsAg biomolecules 
was followed by pulsing with thymidine marked with 
tritium. Growth inhibition was calculated as percentage 
of surviving cells compared to non-treated cells as the 
control (Fig.  3a). Growth inhibition was attained at 
much lower concentrations, when the cells were treated 
with anti-HER-2004  ×  HBsAg, over that attained with 
trastuzumab.
Trastuzumab and both new biomolecular clusters trig-
gered apoptosis (Fig.  3b). The extent of apoptosis pro-
gressed rapidly, but the anti-HER-2001  ×  HBsAg and 
anti-HER-2004  ×  HBsAg induced apoptosis in much 
greater percentage than trastuzumab (~40  %). In all 
cases, this percentage was statistically much higher than 
in the MCF-7—HER-2− cells treated on the identical way 
(Fig. 3c). It was also statistically significantly higher than 
SK-BR-3 cells treated with the isotype antibody.
Trastuzumab and both new biomolecular clusters of 
anti-HER-2  ×  HBsAg caused necrosis (Fig.  3d). At the 
initial stages of apoptosis, many cells were only showing 
outer-membrane display of phosphatidylserine, but were 
not permeable for PI. At the more advanced stages they 
were becoming leaky; thus adding to necrotic counts. 
Both clusters of anti-HER-2  ×  HBsAg caused massive 
necrosis of the SK-BR-3 and the patients’ HER-2+ breast 
cancer cells in the percentages, which were statisti-
cally significantly much higher over those inflicted by 
trastuzumab.
Factors affecting immunotherapeutic efficacy 
of anti‑HER‑2 × HBsAg
The processes of breast cancer cells’ deaths are triggered 
by the specific elements of the patients’ immune system: 
humoral and cellular. We aimed at defining the main fac-
tors triggering them. In particular, we were focused on 
effects of complement concentrations and effector cells 
to target cells ratios (Fig. 4a, b).
Concentrations of the complement systems’ compo-
nents (CS) determine the patients’ ability to fight cancer 
by complement dependent cytotoxicity (CDC). Concen-
trations of the complement systems’ components in our 
tests were adjusted within the ranges of healthy adults 
(Fig. 4a) Our measurements revealed that increasing the 
concentrations of the C1q and C3 resulted in the statis-
tically significant increase in the efficacy of the HER-2+ 
SK-BR-3 and the patients’ HER-2+ breast cancer cells’ 
killing by trastuzumab and anti-HER-2 antibodies as 
compared to labeling with the isotype antibodies or 
labeling of the HER-2− MCF-7 cells. The efficacy was 
statistically significantly much higher, when the HER-
2+ SK-BR-3 and the patients’ HER-2+ breast cancer 
cells were treated with anti-HER-2001  ×  HBsAg, and 
anti-HER-2004 × HBsAg.
Numbers of natural killer cells and cytotoxic lymphocytes 
in the patient’s circulation determine this patient’s ability 
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to execute antibody dependent cell cytotoxicity (ADCC). 
The numbers of the immune cells were adjusted to clini-
cal lab values. Trastuzumab and our anti-HER-2 biosimilar 
antibodies caused the cancer cells’ deaths through ADCC 
already at the ratio of 10:1, but with no statistical differ-
ence between them (Fig. 4b). Anti-HER-2001 × HBsAg, and 
anti-HER-2004 × HBsAg inflicted massive deaths of breast 
cancer cells, which were at statistically significantly much 
higher levels, than those inflicted by trastuzumab and anti-
HER-2 biosimilars. The isotype antibodies did not have any 
impact. The MCF-7 cells and the patients’ breast epithelial 
cells did not show signs of responding to these immuno-
therapeutics in the conditions described. All the measure-
ments were pursued in triplicates. All the data presented 
are representative for all studied. Treatment with the iso-
type antibodies did not have any statistically significant 
impact on the cancer cells’ death rates.
Discussion
Herein, we have presented an entirely new paradigm for 
immunotherapy of cancer patients due to biomolecular 
engineering of synthetic molecules, which are capable 
Fig. 3 Mechanism of action of AVEC: anti-HER-2 × HBsAg. a SK-BR-3 breast cancer cells were labeled for 1–7 h at 37 °C with 0.3 mg/ml trastu-
zumab or anti-HER-2 × HBsAg in full human sera from the HBV—vaccinated patients keeping 10.0 IU/ml anti-HBV. That was followed by studying 
growth inhibition through thymidine incorporation, b The breast cancer cells from the patient with metastatic HER-2+ breast cancer were treated 
as in (a) including fluorescent AVEC: anti-HER-2 x HBsAg, labeling with anti-phosphatidylserine (anti-PS) to detect apoptosis or propidium iodide (PI) 
to detect necrosis. These tests were repeated three times. This route of MOA is representative for all 10 patients’ breast cancer cells. After 1 h only a 
few cells were showing signs of chromatin collapse. After 6 h most of the cells, which were marked as apoptotic by anti-PS (c) were also necrotic. 
Almost 40 % of the cancer cells were apoptotic due to treatment. That more than doubled due to the treatment with anti-HER-2001 × HBsAg or 
anti-HER-2004 × HBsAg. Nearly 10 % were determined necrotic as the result of the treatment with trastuzumab (d). The percentage of the necrotic 
cells due to the treatment with anti-HER-2001 × HBsAg or anti-HER-2004 × HBsAg more than tripled over that attained with trastuzumab
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for interfacing preventive and therapeutic immunities. 
It is a paradigm of redirecting, accelerating, amplify-
ing vaccine-induced immunity therapy against cancer 
(RAAVIIT). It engages both arms of the patients’ immune 
system: innate and adaptive—acquired through vac-
cination against hepatitis B virus. HBsAg is the epitope 
uniquely different from all epitopes displayed on healthy 
human cells. Therefore, the risk of vaccination-induced 
immunity turning against the patients’ own cells, as auto-
immune disease, is unlikely. Therefore, the approach pre-
sented herein offers a promise of being least iatrogenic.
This situation would be very different, if the vac-
cines would be ever developed against cancer cells. Even 
changes in the receptors’ coding sequences, e.g., epider-
mal growth factor 1 variant III (EGFRvIII) mutation dele-
tion, which result in the mutated gene expression product 
as the truncated receptor, still retains large portions of the 
receptors’ wild type. In that scenario, the risk of an over-
lap with the non-mutated portion of the receptor and 
inclusion into the immune response to mount autoim-
munity is higher. Therefore, linking the anti-body against 
a cancer unique molecule with the FDA already approved 
anti-viral vaccine seems to be a safer and faster approach.
Therefore, rather than developing vaccines imitating 
cancer molecules, so that the response would be directly 
targeting patients’ cells, the RAAVIIT approach may be 
more favorable. In RAAVIIT, the immunity is directed 
against a unique immunogen, which remains on the firm 
stand-by. The immune system is only activated either by 
HBsAg—vaccinating immunogen, or by the hot HBV, or 
by that immunogen linked with the anti-HER-2 antibody 
to redirect immune response.
Immunity developed in patients by vaccination relies 
upon generating polyclonal antibodies. Development of 
two immunotherapeutics: trastuzumab and pertuzumab, 
against the same target HER-2, is de facto an attempt of 
reconstructing the response of the natural immune sys-
tem with polyclonal antibodies. Herein, we present a 
way to by-pass the need for developing multiple clones 
of antibodies against HER-2, but rather we use HBsAg, 
which serves as a lightning rod for attracting all the 
clones of antibodies generated by immunization. There-
fore, it amplifies the therapeutic efficacy of the single 
clone of anti-HER-2 to the level equivalent to eliciting 
polyclonal antibodies. With this new strategy, we engage 
the entire immune system against cancer targets; thus 
greatly amplify the therapeutic efficacy.
Moreover, if ever developed, anti-cancer vaccines 
would have to be introduced against multiple cancers and 
assembled into a program, as now by the CDC for viruses 
and bacteria. Otherwise, development of the active, 
strong immune response by a patient suffering from a 
cancer, whose immune system is greatly compromised by 
the first line systemic chemotherapies, is hard. Further-
more, heterogeneity of cancer cells’ population might 
require multiple vaccines.
Furthermore, to develop an active immune response 
to the cancer vaccine may take a very long time. Passing 
Fig. 4 Factors affecting immunotherapeutic efficacy of anti-HER-2 × HBsAg. (a) SK-BR-3 , MCF-7, and the patients’ HER-2+ breast cancer 
cells were treated with trastuzumab, biosimilar anti-HER-2, anti-HBV, and anti-HER-2 × HBsAg in erythrocyte-free blood, in which concentrations of 
the complement system were adjusted according to measuring of C1q and C3 at 37 °C. The experiments were concluded by labeling of the cells 
with propidium iodide. Necrotic cells were counted by flow cytometry. The experiments were repeated three times. Increasing concentrations of 
complement system components resulted in increased efficacy of the breast cancer cells killing. The novel clusters anti-HER-2004 × HBsAg and 
anti-HER-2001 × HBsAg more than doubled the efficacy of the CDC over trastuzumab and anti-HER-2 biosimilars. b SK-BR-3, MCF-7, and the patients’ 
breast cancer cells were treated with trastuzumab, anti-HER-2, anti-HBV, and anti-HER-2 × HBsAg is erythrocyte-free blood, in which the number 
of the immune cells was adjusted in relation to the number of breast cancer cells. Measurements were pursued as in (a). Increasing the ratio of the 
effector immune cells to target cancer cells resulted in proportional increase in efficacy of the breast cancer cells’ killing. The novel clusters anti-
HER-2004 × HBsAg and anti-HER-2001 × HBsAg more than tripled the efficacy of the ADCC over trastuzumab and anti-HER-2 biosimilars
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time works in favor of cancer progression, but against 
patient’s chances of survival. The RAAVIIT secures the 
instantaneity of the immune response.
The FDA approved vaccines and tests determining the 
concentrations of the antibodies in blood of the patients 
are against adw type of hepatitis B virus. The interfac-
ing molecules described herein are utilizing the patients’ 
immunity against those molecules. However, vaccina-
tions against other types of the viruses may result in 
deviations of reading of the adw oriented tests from the 
real levels of immunity [29, 30]. Identifying, the specific 
virus type used for vaccination of the particular patient, 
administering the specific tests, and applying the spe-
cific HBsAg, should be the essential consideration, when 
administering the RAAVIIT to the patients, while assur-
ing high therapeutic safety and efficacy.
The strategy of killing of the breast cancer cells 
designed in this work involves all three mechanisms 
of cell death: growth inhibition, apoptosis, and necro-
sis. This novel strategy also engages both arms of the 
immune system: innate and adaptive. The RAAVIIT’s 
biomolecules designed in this project have two major 
triggers of these mechanisms. First, the antibody por-
tion of the RAAVIIT biomolecule, through the specific 
domains of the Fc, stimulate FcγR on immune cells. 
Moreover, the specific domains bind the C1q elements 
of the complement system, what leads to activation of 
the complement and initiating C3 action. Second, the 
HBsAg portions of the RAAVIIT biomolecules are trig-
gering massive response of both the innate system and 
the active, vaccination induced adaptive immunity. This 
greatly accelerated and amplified response, over the 
passively administered monoclonal antibodies alone, 
explains great efficacy of RAAVIIT.
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